688247 Stock Overview
A specialty pharmaceutical company, develops generic and formulation products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Sinotherapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.77 |
| 52 Week High | CN¥14.00 |
| 52 Week Low | CN¥6.30 |
| Beta | 0.081 |
| 11 Month Change | 9.79% |
| 3 Month Change | 35.47% |
| 1 Year Change | -12.08% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.81% |
Recent News & Updates
Optimistic Investors Push Sinotherapeutics Inc. (SHSE:688247) Shares Up 27% But Growth Is Lacking
Nov 08
Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance
Nov 02Shareholder Returns
| 688247 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.9% | -1.5% | -2.1% |
| 1Y | -12.1% | -9.4% | 2.8% |
Return vs Industry: 688247 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 688247 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 688247 volatility | |
|---|---|
| 688247 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688247 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688247's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 260 | n/a | www.sinotherapeutics.com |
Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China. It offers posaconazole delayed-release tablets, ursodeoxycholic acid capsules, bupropion hydrochloride extended-release tablets, paroxetine extended-release tablets, sevelamer carbonate tablets, and propafenone hydrochloride extended-release capsules. The company provides CRO/CDMO services including pre-formulation study, formulation and process development, clinical sample manufacturing, NDA registration batch manufacturing, quality standard establishment, and regulatory dossier document preparation and submission.
Sinotherapeutics Inc. Fundamentals Summary
| 688247 fundamental statistics | |
|---|---|
| Market cap | CN¥4.84b |
| Earnings (TTM) | CN¥109.56m |
| Revenue (TTM) | CN¥449.12m |
44.1x
P/E Ratio10.8x
P/S RatioIs 688247 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688247 income statement (TTM) | |
|---|---|
| Revenue | CN¥449.12m |
| Cost of Revenue | CN¥204.95m |
| Gross Profit | CN¥244.17m |
| Other Expenses | CN¥134.60m |
| Earnings | CN¥109.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 54.37% |
| Net Profit Margin | 24.40% |
| Debt/Equity Ratio | 0% |
How did 688247 perform over the long term?
See historical performance and comparison